Abstract: The invention features compositions and methods for the increased production of mevalonate, isoprene, isoprenoid precursor molecules, and/or isoprenoids in microorganisms via the heterologous expression of the mvaE and mvaS genes from the organisms Listeria grayi DSM 20601, Enterococcus faecium, Enterococcus gallinarum EG2, and Enterococcus casseliflavus.
Type:
Application
Filed:
October 15, 2014
Publication date:
February 5, 2015
Inventors:
Zachary Q. BECK, Michael C. Miller, Caroline M. Peres, Yuliya A. Primak, Jeff P. Pucci, Derek H. Wells
Abstract: The present invention relates to a novel Listeria bacteriophage designated ProCC P825. In particular, the present invention relates to the endolysin PlyP825 encoded by the novel phage ProCC P825 and uses of the novel endolysin PlyP825 for controlling Listeria contamination and infection.
Type:
Application
Filed:
May 29, 2012
Publication date:
February 5, 2015
Applicant:
DSM IP ASSETS B.V.
Inventors:
Holger Grallert, Julia Lorenz, Anna Scherzinger
Abstract: The present invention is based upon the identification of a number of antigens derived from species of the genus Teladorsagia, which can be used to raise immune responses in animals—particularly those animals susceptible or predisposed to infection by (or with) one or more Teladorsagia species. The antigens may be exploited to provide compositions and vaccines for raising protective immune responses in animals—the protective immune responses serving to reduce, prevent, treat or eliminate Teladorsagia infections/infestations.
Type:
Application
Filed:
February 4, 2013
Publication date:
February 5, 2015
Inventors:
Jacqueline Matthews, Alasdair Justice Nisbet, David Knox
Abstract: The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed.
Abstract: The purpose of the present invention is to provide: a peptide having an affinity for silicon nitride; a polynucleotide encoding the peptide; an expression vector for expressing the peptide having an affinity for silicon nitride; an expression vector for expressing a peptide fusion protein that comprises the peptide having an affinity for silicon nitride and a target protein; a transformant obtained by introducing the expression vector into a host cell; a peptide fusion protein obtained from the transformant; a silicon nitride substrate to which a peptide having an affinity for silicon nitride has been bonded; a method for immobilizing a target protein to a silicon nitride substrate; a composition for immobilizing a target protein to a silicon nitride substrate, the composition comprising a peptide having an affinity for silicon nitride; and a linker for immobilizing a target protein to a silicon nitride substrate, the linker comprising a peptide having an affinity for silicon nitride.
Abstract: The present disclosure relates to mutant thermostable glycosyl hydrolases family 7 enzymes, including mutant Trichoderma reesei endoglucanase I. In particular, the present disclosure relates to mutant thermostable enzymes, compositions containing the enzymes, and methods of use thereof.
Type:
Application
Filed:
August 11, 2011
Publication date:
February 5, 2015
Applicant:
The Regents of the University of California
Inventors:
Harshal Akshay Chokhawala, Tae-Wan Kim, Harvey W. Blanch, Douglas S. Clark
Abstract: This document describes biochemical pathways for producing isoprene by forming two vinyl groups in a central precursor produced from isobutyryl-CoA, 3-methyl-2-oxopentanoate, or 4-methyl-2-oxopentanoate as well as recombinant hosts for producing isoprene.
Type:
Application
Filed:
August 5, 2014
Publication date:
February 5, 2015
Inventors:
Adriana Leonora Botes, Alex Van Eck Conradie
Abstract: The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragm assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.
Type:
Application
Filed:
August 5, 2014
Publication date:
February 5, 2015
Applicant:
SYNTAXIN LIMITED
Inventors:
Andreas Rummel, Tanja Weil, Aleksandrs Gutcaits
Abstract: The present disclosure relates to polypeptides having transaminase activity, polynucleotides encoding the polypeptides, and methods of using the polypeptides.
Type:
Application
Filed:
October 20, 2014
Publication date:
February 5, 2015
Inventors:
Christopher K. Savile, Emily Mundorff, Jeffrey C. Moore, Paul N. Devine, Jacob M. Janey
Abstract: Recombinant microbial cells and methods for producing 5-hydroxytryptophan (5HTP) using such cells are described. More specifically, the recombinant microbial cell comprises an exogenous gene encoding an L-tryptophan hydroxylase, and means for providing tetrahydrobiopterin (THB). Related sequences and vectors for use in preparing such recombinant microbial cells are also described.
Type:
Application
Filed:
February 28, 2013
Publication date:
February 5, 2015
Inventors:
Eric Michael Knight, Jiangfeng Zhu, Jochen Förster, Hao Luo
Abstract: The disclosure relates to a Gram negative bacterial cell that is transformed with a nucleic acid molecule that encodes a Gram positive twin-arginine translocase and including methods for the production of polypeptides.
Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Type:
Application
Filed:
October 20, 2014
Publication date:
February 5, 2015
Inventors:
Suchindra Maiyuran, Randall Kramer, Paul Harris
Abstract: The present invention relates to a method of selecting a protein variant having modified immunogenicity as compared to the parent protein comprising the steps obtaining antibody binding peptide sequences, using the sequences to localise epitope sequences on the 3-dimensional structure of parent protein, defining an epitope area including amino acids situated within 5 ? from the epitope amino acids constituting the epitope sequence, changing one or more of the amino acids defining the epitope area of the parent protein by genetical engineering mutations of a DNA sequence encoding the parent protein, introducing the mutated DNA sequence into a suitable host, culturing said host and expressing the protein variant, and evaluating the immunogenicity of the protein variant using the parent protein as reference. The invention further relates to the protein variant and use thereof, as well as to a method for producing said protein variant.
Type:
Application
Filed:
October 15, 2014
Publication date:
February 5, 2015
Inventors:
Erwin Ludo Roggen, Steffen Ernst, Allan Svendsen, Esben Peter Friis, Claus Von Der Osten
Abstract: The present invention relates to a quinolinic acid-producing recombinant microorganism expressing a fusion protein of L-aspartate oxidase and quinolinate synthase linked via a linker, and a method for producing quinolinic acid using the same.
Type:
Application
Filed:
January 3, 2013
Publication date:
February 5, 2015
Inventors:
Yong Uk Shin, So Young Kim, In Kyung Heo, Ju Eun Kim, Sung Kwang Son, Jae Hee Lee, Ji Hyun Lee, Chang Gyeom Kim
Abstract: The present invention relates to a microorganism having L-tryptophan productivity and a method for producing L-tryptophan using the same. More precisely, the present invention relates to the recombinant E. coli strain CJ600 (KCCM 10812P) having tryptophan productivity produced from the mutant form (KFCC 10066) of E. coli having L-phenylalanine productivity, wherein tryptophan auxotrophy is released, L-phenylalanine biosynthesis is blocked but tryptophan productivity is enhanced by reinforcing the gene involved in tryptophan biosynthesis, and a method of producing L-tryptophan using the same.
Type:
Grant
Filed:
December 28, 2007
Date of Patent:
February 3, 2015
Assignee:
CJ Cheiljedang Corporation
Inventors:
Jae-yeong Ju, Hyang Choi, Eun-sung Koh, Ji-sun Lee, Jin-ho Lee, So-young Kim, Chang-hyun Jin, Young-hoon Park
Abstract: Expression vector systems are provided for increased production of a recombinant GDF-5 (rhGDF-5) protein. Also provided are transformed host cells that were engineered to produce and express high levels of rhGDF-5 protein. Methods for production and high expression of rhGDF-5 protein are disclosed herein. The methods of enhancing production and protein expression of rhGDF-5 protein as disclosed are cost-effective, time-saving and are of manufacturing quality.
Abstract: The present invention relates to a method for producing a product of a reaction catalysed by a nitrilase, which method comprises the steps (i) providing a microorganism comprising said nitrilase located on its surface, and/or a membrane preparation of said microorganism, and (ii) contacting the microorganism and/or the membrane preparation thereof with one or more nitrilase substrates under conditions compatible with nitrilase activity. The present invention further relates to a method for producing enantiomerically pure (R)-mandelic acid using the nitrilase-displaying whole cell biocatalyst or membrane preparation thereof for the conversion of racemic mandelonitrile.
Type:
Grant
Filed:
November 16, 2010
Date of Patent:
February 3, 2015
Assignee:
Zyrus Beteiligungsgesellschaft mbH & Co. Patente I KG
Inventors:
Joachim Jose, Ruth Maas, Christian Detzel
Abstract: The present invention relates to isolated polypeptides having xylanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Abstract: The present invention relates to variants of a parent antimicrobial peptide. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
Type:
Application
Filed:
August 11, 2014
Publication date:
January 29, 2015
Applicant:
ADDENIUM BIOTECH APS
Inventors:
Hans-Henrik Kristensen Hoegenhaug, Per Holse Mygind, Thomas Kruse, Dorotea Raventos Segura, Dorthe Hoj Sandvang, Soren Neve
Abstract: The present disclosure relates to a collection of novel muteins derived from human ?1m (or a1m) polypeptide or a functional homologue thereof. The disclosure further refers to a ?1m mutein capable of specifically binding to one or more targets other than a target to which wild-type ?1m binds. The disclosure also relates to a method for producing such collection of muteins and a method for isolating a mutein capable of binding one or more such non-natural targets of wild-type ?1m polypeptide. These aspects are made possible due to, e.g, the structural elucidation of ?1m disclosed herein by the present inventors, an appreciation of ligand-binding sights thereof and, hence, an understanding of which amino acid positions are most suitable for mutagenesis for re-engineering specificity and affinity for any given target while maintaining the secondary and/or tertiary structure of ?1m.
Type:
Application
Filed:
January 31, 2013
Publication date:
January 29, 2015
Inventors:
Arne Skerra, Winfried Meining, Evelyn Eggenstein
Abstract: A novel monoclonal antibody and like antigen-binding molecules against transmembrane protein with EGF-like and two follistatin-like domains 2 (TMEFE2) are provided with unique immunological and biological properties useful in the therapy of affective disorders such as depression and bipolar disorders as well as anxiety disorders. In addition, pharmaceutical compositions and kits comprising such antibody and derivatives thereof are described.
Abstract: Embodiments of the present invention concerns methods and compositions for the construction of a series of vectors containing a chemical sensing module to assess the production of a chemical compound by a microorganism.
Type:
Application
Filed:
February 27, 2014
Publication date:
January 29, 2015
Applicant:
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Inventors:
Ryan T. Gill, Michael D. Lynch, Tirzah Y. Mills
Abstract: The present invention relates to isolated polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Abstract: The present invention relates to variants of a parent cellobiohydrolase II. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
Abstract: The invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum. The protein binds specifically to nerve cells with a higher affinity as the native neurotoxin. The invention also relates to a method for the production of transport protein, the nucleic acids coding for the transport protein, the transport protein containing pharmaceutical and cosmetic compositions and use thereof.
Abstract: Establishment of an effective and uniform vaccine development strategy is key to conquering current and emerging infectious diseases. Despite successes against an array of bacterial agents, current approaches to vaccine development are as diverse as the microbes they target and require adjuvants that often have limited efficacy and/or toxic side effects. As a consequence, vaccine discovery is often slow, inefficient, and unsuccessful in the case of many high priority pathogens. The present disclosure suggests that vaccine generation for bacterial pathogens can be improved by optimizing the efficiency of processing/presentation of a bacterial immunogen via the targeting of immunogen to CR2 and/or TLR2 on APCs. This approach not only yields an adjuvant-free mucosal vaccine against a Category A biothreat agent, but also establishes a novel genetic approach/platform for vaccine development, which is applicable to many other infectious agents, thereby profoundly impacting preventive medicine/public health.
Type:
Application
Filed:
January 22, 2013
Publication date:
January 29, 2015
Applicant:
ALBANY MEDICAL COLLEGE
Inventors:
Karsten Hazlett, Edmund Gosselin, Timothy Sellati, Tiffany Zarrella
Abstract: The present invention relates to expression cassettes comprising at least one transcription regulating nucleotide sequence obtainable from the group of genes of monocotyledonous plants consisting of caffeoyl-CoA-O-methyltransferase genes, C8,7-sterol isomerase genes, hydroxyproline-rich glycoprotein (HRGP) genes, lactate dehydrogenase genes, and chloroplast protein 12 like genes. More preferably the transcription regulating sequences are obtainable from Zea mays or Oryza sativa. The transcription regulating sequences are especially useful for root/kernel-preferential, leaf/endosperm-preferential, root/silk/kernel-preferential, or constitutive expression.
Type:
Application
Filed:
October 3, 2014
Publication date:
January 29, 2015
Inventors:
Hee-Sook Song, Marc Morra, Christian Dammann, Christina E. Roche, Effie Toren, Alleson Dobson
Abstract: The present invention relates to a nucleic acid aptamer molecule that includes a domain that binds to an estrogen receptor, molecular complexes that include the nucleic acid aptamer molecule and an estrogen receptor, and constructed DMA molecules and expression systems, as well as host cells, that the contain an RNA aptamer molecule of the invention. Use of these aptamers and encoding constructs to inhibiting estrogen receptor activity in a cell and to treat estrogen receptor-positive cancers is also described.
Type:
Application
Filed:
August 16, 2012
Publication date:
January 29, 2015
Applicant:
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK AT ALBANY
Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds. The engineered ketoreductase polypeptides are optimized for catalyzing the conversion of N-methyl-3-keto-3-(2-thienyl)-1-propanamine to (S)—N-methyl-3-hydroxy-3-(2-thienyl)-1-propanamine.
Type:
Application
Filed:
October 1, 2014
Publication date:
January 29, 2015
Inventors:
Christopher Savile, John M. Gruber, Emily Mundorff, Gjalt W. Huisman, Steven J. Collier
Abstract: A phage display system is provided comprising a mutant phage-infected host cell adapted to express a peptide of interest fused to a phage capsid protein, wherein the mutant phage includes a nonsense mutation which prevents expression of the capsid protein as a functional protein, and wherein expression of the peptide of interest is controlled by an inducible repressor and by a suppressor that suppresses the nonsense mutation.
Abstract: The invention provides a chimeric antigen receptor (CAR) (a) an antigen binding domain of HN1 or SS, a transmembrane domain, and an intracellular T cell signaling domain, or (b) an antigen binding domain of SS1, a transmembrane domain, an intracellular T cell signaling domain, and a granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor 2 leader. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
Type:
Application
Filed:
March 5, 2013
Publication date:
January 29, 2015
Inventors:
Steven A. Feldman, Steven A. Rosenberg, Ira H. Pastan
Abstract: The invention provides mutants of GAS57 (Spy0416) which are unable to cleave IL-8 and similar substrates but which still maintain the ability to induce protection against S. pyogenes. The invention also provides antibodies which specifically bind to GAS57 and which inhibit its ability to cleave IL-8 and similar substrates. The mutants are useful, inter alia, in vaccine compositions to induce protection against S. pyogenes. The antibodies are useful, e.g., as therapeutics for treating S. pyogenes infections.
Type:
Application
Filed:
October 13, 2014
Publication date:
January 29, 2015
Inventors:
Immaculada Margarit Y Ros, Guido Grandi, Chiara Zingaretti
Abstract: Provided is a mutant of propionyl-CoA transferase from Clostridium propionicum that can convert lactate into lactyl-CoA with high efficiency in a method of preparing a polylactate (PLA) or PLA copolymer using microorganisms. Unlike conventional propionyl-CoA transferase which is weakly expressed in E. coli, when a mutant of propiony-CoA transferase from Clostridium propionicum is introduced into recombinant E. coli, lactyl-CoA can be supplied very smoothly, thereby enabling highly efficient preparation of polylactate (PLA) and PLA copolymer.
Type:
Application
Filed:
October 7, 2014
Publication date:
January 29, 2015
Inventors:
Si Jae PARK, Taek Ho YANG, Hye Ok KANG, Sang Hyun LEE, Eun Jung LEE, Tae Wan KIM
Abstract: To produce quinolinate effectively, a L-aspartate oxidase variant that the feedback regulation by nicotinic acid or NAD is released, and a microorganism including the L-aspartate oxidase variant are provided. Quinolinate may be effectively produced by culturing of the microorganism including the L-aspartate oxidase variant.
Type:
Application
Filed:
July 25, 2014
Publication date:
January 29, 2015
Inventors:
So Young KIM, Yong Uk SHIN, In Kyung HEO, Ju Eun KIM, Kwang Ho NA, Chang Il SEO, Sung Kwang SON, Jae Hee LEE
Abstract: The present invention relates to a recombinant microorganism comprising one or more nucleotide sequence(s) encoding: a polypeptide having ent-copalyl pyrophosphate synthase activity; a polypeptide having ent-Kaurene synthase activity; a polypeptide having ent-Kaurene oxidase activity; and a polypeptide having kaurenoic acid 13-hydroxylase activity, whereby expression of the nucleotide sequence(s) confer(s) on the microorganism the ability to produce at least steviol. The recombinant microorganism may also be capable of expressing one or more UDP-glucosyltransferases such that the microorganism is capable of producing one or more steviol glycosides.
Type:
Application
Filed:
January 23, 2013
Publication date:
January 29, 2015
Inventors:
Martin Lehmann, Joshua Trueheart, Priscilla Zwart Jens, Liang Wu, Viktor Marius Boer, Cornelis Maria Jacobus Sagt, Manoj Kumar, Bernard Meijrink, Marco Alexander Van Den Berg
Abstract: The invention provides non-naturally occurring microbial organisms containing caprolactone pathways having at least one exogenous nucleic acid encoding a butadiene pathway enzyme expressed in a sufficient amount to produce caprolactone. The invention additionally provides methods of using such microbial organisms to produce caprolactone by culturing a non-naturally occurring microbial organism containing caprolactone pathways as described herein under conditions and for a sufficient period of time to produce caprolactone.
Type:
Grant
Filed:
November 2, 2012
Date of Patent:
January 27, 2015
Assignee:
Genomatica, Inc.
Inventors:
Anthony P. Burgard, Robin E. Osterhout, Priti Pharkya, Mark J. Burk
Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.
Type:
Grant
Filed:
December 21, 2009
Date of Patent:
January 27, 2015
Assignees:
Biogen Idec International Neuroscience GmbH, University of Zurich
Inventors:
Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
Abstract: To produce a bacterial microcompartment shell, or a designed shell based on naturally occurring bacterial microcompartment shells in a new host organism, a synthetic operon is constructed that contains the desired shell protein genes and translation efficiency is controlled by host specific ribosomal binding sites. Proteins or other molecules can be encapsulated in the microcompartment shells by various methods described herein. The constructs can also be used to express self-assembling sheets comprised of shell proteins.
Type:
Application
Filed:
March 14, 2014
Publication date:
January 22, 2015
Applicant:
The Regents of the University of California
Inventors:
Cheryl A. Kerfeld, Jonathan K. Lassila, James N. Kinney
Abstract: The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO: 1 and fragments or derivatives thereof. The present invention further relates to fusion proteins comprising said polypeptide and an additional peptide stretch fused to said polypeptide at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said polypeptide or fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said polypeptide or fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, as cosmetic substance or as sanitizing agent.
Abstract: Aspects of the invention provide engineered endonucleases that are characterized by both a long recognition sequence and specific cleavage outside of the recognition site. Engineered endonucleases of the invention are useful for manipulating long pieces of DNA.
Type:
Application
Filed:
May 5, 2014
Publication date:
January 22, 2015
Applicant:
Celexion, LLC
Inventors:
Shaun M. Lippow, Dasa Lipovsek, Patricia M. Aha
Abstract: The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster3 of BCMA, and the second binding domain is capable of binding to the Tcell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.
Type:
Application
Filed:
November 15, 2012
Publication date:
January 22, 2015
Inventors:
Peter Kufer, Tobias Raum, Patrick Hoffmann, Roman Kischel, Ralf Lutterbuese, Doris Rau, Paul Adam, Eric Borges, Barbara Hebeis, Susanne Hipp
Abstract: Disclosed are compounds, compositions, and methods relating to fluoride aptamers, fluoride-responsive riboswitches, fluoride-regulated expression constructs, fluoride transporters, nucleic acids encoding fluoride transporters, expression constructs encoding fluoride transporters, and cells containing or including any combination of these.
Type:
Application
Filed:
September 17, 2012
Publication date:
January 22, 2015
Inventors:
Ronald Breaker, Jenny Baker, Narasimhan Sudarsan, Zasha Weinberg, Adam Roth, Tyler Ames, James Nelson
Abstract: Disclosed is an IgG Fc fragment useful as a drug carrier. A recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment are disclosed. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.
Type:
Application
Filed:
July 9, 2014
Publication date:
January 22, 2015
Applicant:
HANMI SCIENCE CO., LTD.
Inventors:
Sung Youb JUNG, Jin Sun Kim, Geun Hee Yang, Se Chang Kwon, Gwan Sun Lee
Abstract: A mutant butyraldehyde dehydrogenase (Bld), a polynucleotide having a nucleotide encoding the mutant, a vector including the polynucleotide, a microorganism including a nucleotide encoding the mutant, and a method of producing 1,4-butanediol using the same.
Type:
Application
Filed:
July 18, 2014
Publication date:
January 22, 2015
Inventors:
Ji-eun KIM, Jin-woo Park, Jin-hwan Park, Yu-kyung Jung, Hwa-young Cho, Jae Chan Park, Kwang-myung Cho
Abstract: A fusion polypeptide capable of binding simultaneously to angiopoietin 2, VEGF-C and VEGF-D; or capable of binding simultaneously to VEGF-C and VEGF-D, and methods for the preparation and use thereof.
Type:
Application
Filed:
July 21, 2014
Publication date:
January 22, 2015
Inventors:
Kwang Hoon LEE, Hyung-Chan Kim, Sang Yeul Han, Seok Kyun Kim, Kyung Eun Kim
Abstract: Purified Ref polypeptides with increased nuclease site-specific targeting activity, recombinant nucleic acids and cells for expression of such Ref polypeptides, and methods for using the Ref polypeptides in combination with RecA protein and variants thereof to effect targeted nuclease cleavage of a DNA duplex are disclosed.
Type:
Application
Filed:
July 21, 2014
Publication date:
January 22, 2015
Inventors:
Michael Matthew Cox, Angela Jo Gruber, Tayla Maria Olsen